+

WO2006106438A3 - Procedes de modulation de l'activite de ppar - Google Patents

Procedes de modulation de l'activite de ppar Download PDF

Info

Publication number
WO2006106438A3
WO2006106438A3 PCT/IB2006/001421 IB2006001421W WO2006106438A3 WO 2006106438 A3 WO2006106438 A3 WO 2006106438A3 IB 2006001421 W IB2006001421 W IB 2006001421W WO 2006106438 A3 WO2006106438 A3 WO 2006106438A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulators
individual
disclosed
ppar activity
ppar
Prior art date
Application number
PCT/IB2006/001421
Other languages
English (en)
Other versions
WO2006106438A2 (fr
Inventor
Sorensen Alexandra M P Santana
Karsten Kristiansen
Lise Madsen
Rasmus K Petersen
Original Assignee
Evolva Sa
Sorensen Alexandra M P Santana
Karsten Kristiansen
Lise Madsen
Rasmus K Petersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolva Sa, Sorensen Alexandra M P Santana, Karsten Kristiansen, Lise Madsen, Rasmus K Petersen filed Critical Evolva Sa
Publication of WO2006106438A2 publication Critical patent/WO2006106438A2/fr
Publication of WO2006106438A3 publication Critical patent/WO2006106438A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédés de modulation de l'activité du récepteur activé de la prolifération des peroxysomes (PPAR) chez un individu : administration de quantité thérapeutiquement efficace de composé caractérisé par la présence de chaîne hydrocarbure à longueur variable, par exemple 10-32 atomes de carbone, se terminant à une extrémité par un groupe -COOH ou un sel, ou un dérivé fonctionnel correspondant. Les composés peuvent être représentés par les formules A et B, sachant que R1, R2, R3, R4, R5, R6 et X sont tels que spécifiés dans la description.
PCT/IB2006/001421 2005-01-11 2006-01-11 Procedes de modulation de l'activite de ppar WO2006106438A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500051 2005-01-11
DKPA200500051 2005-01-11
US67670805P 2005-05-02 2005-05-02
US60/676,708 2005-05-02

Publications (2)

Publication Number Publication Date
WO2006106438A2 WO2006106438A2 (fr) 2006-10-12
WO2006106438A3 true WO2006106438A3 (fr) 2007-05-18

Family

ID=36940711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001421 WO2006106438A2 (fr) 2005-01-11 2006-01-11 Procedes de modulation de l'activite de ppar

Country Status (1)

Country Link
WO (1) WO2006106438A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014633D0 (en) 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
JP6315536B2 (ja) * 2014-01-29 2018-04-25 岩手県 Ｐｐａｒ活性化剤
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
EP3515422A1 (fr) 2016-09-21 2019-07-31 Avexxin AS Composition pharmaceutique
MX391168B (es) * 2017-07-07 2025-03-21 The Us Secretary Department Of Health & Human Services Derivados de acido graso y su uso.
EP4076649A1 (fr) * 2019-12-19 2022-10-26 Liminal Biosciences Limited Acides carboxyliques contenant un cycloalkyle et leurs utilisations
EP4199895A4 (fr) * 2020-08-18 2024-11-20 The Regents of The University of Michigan Produits d'acides aminés n-acyle et leurs utilisations
WO2025023183A1 (fr) * 2023-07-21 2025-01-30 国立大学法人大阪大学 Métabolite d'acide gras qui supprime une maladie inflammatoire de l'intestin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022848A1 (fr) * 1993-03-29 1994-10-13 Pace Asciak Cecil R Analogues d'hepoxiline utilisables comme agents anti-inflammatoires
WO2001010422A2 (fr) * 1999-08-04 2001-02-15 Hsc Research And Development Limited Partnership Analogues d'hepoxiline
WO2002038157A2 (fr) * 2000-11-09 2002-05-16 The Hospital For Sick Children Inhibiteurs de la formation et de l'activite de la thromboxane
WO2003099285A1 (fr) * 2002-05-28 2003-12-04 The Hospital For Sick Children Compositions comprenant des analogues de l'hepoxiline et leur utilisation dans le traitement du cancer
WO2004104022A2 (fr) * 2003-05-16 2004-12-02 The General Hospital Corporation Compositions contenant un facteur chimio-tactique epithelial pathogene (eicosanoide et hepoxiline a3), leurs inhibiteurs et leurs procedes d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022848A1 (fr) * 1993-03-29 1994-10-13 Pace Asciak Cecil R Analogues d'hepoxiline utilisables comme agents anti-inflammatoires
WO2001010422A2 (fr) * 1999-08-04 2001-02-15 Hsc Research And Development Limited Partnership Analogues d'hepoxiline
WO2002038157A2 (fr) * 2000-11-09 2002-05-16 The Hospital For Sick Children Inhibiteurs de la formation et de l'activite de la thromboxane
WO2003099285A1 (fr) * 2002-05-28 2003-12-04 The Hospital For Sick Children Compositions comprenant des analogues de l'hepoxiline et leur utilisation dans le traitement du cancer
WO2004104022A2 (fr) * 2003-05-16 2004-12-02 The General Hospital Corporation Compositions contenant un facteur chimio-tactique epithelial pathogene (eicosanoide et hepoxiline a3), leurs inhibiteurs et leurs procedes d'utilisation

Also Published As

Publication number Publication date
WO2006106438A2 (fr) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2006106438A3 (fr) Procedes de modulation de l'activite de ppar
WO2008060626A3 (fr) Composés modulateurs de fonction trpv3
WO2006066133A3 (fr) Inhibiteurs d'histone desacetylase
EA200702470A1 (ru) Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
WO2009050561A3 (fr) Procédé pour améliorer l'adsorption d'un inhibiteur sur une partie de puits de pétrole
WO2009064854A3 (fr) Anticorps humanises contre tl1a
TNSN08140A1 (fr)
WO2008030367A3 (fr) Inhibiteurs sélectifs de la myostatine
WO2006018662A3 (fr) Derives d'uree arylique
MY153971A (en) Sulfonamides as trpm8 modulators
IS2744B (is) Tæki til þess að öngla, ásamt möguleika til þess að beita línu
DE602005017653D1 (de) Enyzmgranulat
WO2010093849A3 (fr) Dérivés de la phénylalanine-amide utiles pour le traitement de maladies et états liés à l'insuline
WO2006122319A3 (fr) Inhibiteurs d'histone deacetylase
WO2007136759A3 (fr) Procédé de traitement et de prévention de troubles oculaires
WO2007081835A3 (fr) Modulateurs du facteur 1 inductible par l'hypoxie et utilisations associees
WO2007143422A3 (fr) Composés de pyridyl amide substitués utilisés comme modulateurs du récepteur de l'histamine h3
NO20055370D0 (no) Alfa-substituert karboksylsyre som PPAR modulatorer
WO2007142905A3 (fr) Dérivés de 1-sulfonylindazolylamine et de 1-sulfonylindazolylamide en tant que ligands de la 5-hydroxytryptamine-6
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
WO2008059339A3 (fr) Dérivés d'isoquinoline comme modulateurs des récepteurs vanilloïdes
ATE498986T1 (de) Verfahren und vorrichtung zum aktivieren der stromeinsparung, wenn keine daten über einen logischen medienkanal übertragen werden
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
WO2004075840A3 (fr) Modulateurs selectifs de recepteurs de glucocorticoides non steroidaux
WO2006124865A3 (fr) Biaryles utiles en tant que modulateurs des canaux ioniques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06755923

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6755923

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载